Skip to main content
Premium Trial:

Request an Annual Quote

ALPCO Calprotectin Immunoturbidimetric Assay

American Laboratory Products Company (ALPCO) has launched its FDA-cleared Calprotectin Immunoturbidimetric Assay to aid in the diagnosis of inflammatory bowel disease, specifically Crohn's disease and ulcerative colitis, and help differentiate IBD from irritable bowel syndrome. The Salem, New Hampshire-based firm said the quantitative immunoassay for fecal calprotectin in a stool sample performs with 90.5 percent clinical sensitivity and 93.4 percent clinical specificity, and its low false-positive rate helps clinicians prioritize patients for confirmatory colonoscopies and minimize unnecessary procedures.